Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

- Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial of MM-402 in 2023 - Cash runway to fund current operating plan into first half of 2025 - Company to host a virtual analyst and investor day in the first half of 2023 NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2023. "Following a year of continued strong execution, our progress in 2022 has set the stage for a meaningful 2023, a year in which we plan to further elucidate the potential of our MM-120 product candidate in generalized anxiety disorder (GAD) and initiate the first clinical trial for our MM-402 program," stated Rob Barrow, Chief Executive Officer.

MindMed Provides Corporate Update and 2023 Outlook

Atai Life Sciences BV

COMPASS Pathways

Cybin

Seelos Therapeutics

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.

Scrutinizing Psychedelic Stocks

NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference. Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference Format: Panel presentation and one-on-one investor meetingsPanel Date: Tuesday, December 13, 2022 Panel Time: 11:00 a.m.

MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference

Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) Inc has earned a repeat ‘Speculative Buy' rating with a lowered price target of US$18 from US$22 per share from Canaccord Genuity (TSX:CF, LSE:CF) analysts following the release of its third-quarter results last week. The biotechnology company's shares are currently trading at about US$2.60 per share.

MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelved

NEW YORK , Nov. 11, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022. Jefferies London Healthcare Conference Format: Presentation and one-on-one investor meetingsPresentation Date: Wednesday, November 16, 2022 Presentation Time: 3:50 p.m.

MindMed to Participate in the Jefferies London Healthcare Conference

Mind Medicine (MindMed), Inc. (NASDAQ:MNMD ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Robert Barrow - CEO & Director Schond Greenway - CFO Daniel Karlin - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright & Co. Sepehr Manochehry - Eight Capital Operator Good day, and welcome to the Mind Medicine Third Quarter 2022 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed), Inc. (MNMD) Q3 2022 Earnings Call Transcript

– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 – – Advanced IND-enabling studies for MM-402 and initiated Phase 1 investigator-initiated trial in Q3 2022 –  – Cash and cash equivalents of $154.5 million expected to fund current operating plan into first half of 2025 - – Company to host conference call today at 8:30 AM ET – NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2022. "We are pleased with the progress made in the third quarter as we continue executing on our core development programs, MM-120 and MM-402, and accelerating preparations for Phase 3 studies – all with the goal of bringing our treatments to market as efficiently as possible for the benefit of both patients and shareholders.

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

NEW YORK , Nov. 3, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

Jupiter Wellness

NanoViricides

Oblong

Smart Sand

Capstone Green Energy

Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

Applied Therapeutics Inc

Cabaletta Bio

Doma Holdings

Canoo

Nine Energy Service

Quoin Pharmaceuticals Ltd

Founder SPAC

Viking Therapeutics

Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022

The support for legalizing drugs -- such as those being studied by the company -- grows with a U.S. senator's tweet.

Why Mind Medicine Zoomed 8% Higher on Tuesday

Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Buy According To Top Wall Street Analysts

Akero Therapeutics Inc

Applied DNA Sciences

Avenue Therapeutics

HeartBeam

Immuneering Corp

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

Penny stocks with 1000% upside potential according to these Wall Street analysts. The post 3 Penny Stocks With 1,000% Upside Potential According To These Analysts appeared first on Penny Stocks to Buy, Picks, News and Information.

3 Penny Stocks With 1,000% Upside Potential According To These Analysts

NEW YORK , Oct. 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022. Cantor Fitzgerald Neurology & Psychiatry Conference Format: Panel presentation and one-on-one investor meetingsPanel Title: "Tripping our way to a new treatment paradigm for psychiatric disorders: intermittent therapy vs chronic treatment"Panel Date: Thursday, October 6, 2022 Panel Time: 12:10 p.m.

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

The company is going back into the lab, and investors are eager to see what it discovers.

Why Mind Medicine Stock Triumphed on Tuesday

- Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects - NEW YORK , Oct. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation of a Phase 1 investigator-initiated trial led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB).

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

A highly dilutive new round of financing is making the stock behave like a yo-yo.

Why Mind Medicine Stock Soared on a Down Day for the Market

PolyPid

Senti Biosciences Inc

Biotech penny stocks to watch as stock market crash continues today. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues

Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary SHERIDAN, Wyo. , Sept. 28, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September 27, 2022 (the "Dilutive Offering").

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign

Shares of psychedelics company Mind Medicine Inc. slid 50% Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares.

Stock of psychedelics company MindMed slides 50% after it sells fresh shares

The maker of psychedelic drugs announced the pricing of its latest public offering.

Why Mind Medicine (MindMed) Stock Is Crashing Today

MindMed (NASDAQ: MNMD ) stock is plunging 51% today after the drug maker announced yesterday shortly before the market closed that it would sell an undisclosed number of common shares of MMED stock, along with an undisclosed number of warrants. The company did not indicate the price at which the securities would be sold.

Why Is MindMed (MNMD) Stock Plunging 51% Today?

Shares of psychedelics company Mind Medicine Inc. MNMD, +6.43% slid 35.6% in premarket trade Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares. The offering priced at $4.25 a share, below the stock's closing price Tuesday of $6.12.

News for Mind Medicine MindMed Stock (MNMD)